SBI Investment Portfolio Company G2GBIO Selected as a Constituent of Korea Investment Management’s New ETF ‘ACE K-Bio KOSDAQ Active’

• G2GBIO, an SBI Investment portfolio company and long-acting drug delivery system (DDS) platform company, has been selected as a constituent of ‘ACE K-Bio KOSDAQ Active,’ a new ETF listed by Korea Investment Management on July 21.
• The ETF focuses on KOSDAQ-listed biotechs specializing in technology licensing (license-out). G2GBIO was included in the obesity treatment category together with D&D Pharmatech, alongside leading biotechs such as Alteogen, LigaChem Biosciences, Voronoi and Oscotec.
• As competition intensifies in the global obesity treatment market to develop long-acting formulations that extend dosing intervals, this shows that G2GBIO's platform technology is also viewed by capital markets as a promising candidate for technology licensing.

The full article is available at the link below.

https://www.thebell.co.kr/front/newsview.asp?click=F&key=202607200924214880108662